NCT05587998View on ClinicalTrials.gov

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions
Opioid Use Disorder
Interventions
DRUG

Morphine

Participants will receive IV dose of Morphine as stated in arm description.

DRUG

AZD4041

Participants will receive oral doses of AZD4041 as stated in arm description.

OTHER

Placebo

Participants will receive oral doses of placebo as stated in arm description.

Trial Locations (1)

66212

Research Site, Overland Park

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY